title: Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
abstract: Chemotherapy-induced nausea and vomiting is a significant clinical issue which affects patient's quality of life and treatment decisions. Significant improvements in the control of chemotherapy-induced nausea and vomiting have occurred in the past 15 years with the introduction of new antiemetic agents 5-HT3, receptor antagonists, neurokinin-1 (NK-1) receptor antagonists, and olanzapine. Aprepitant was the first NK-1 receptor antagonist introduced (2003) for the prevention of chemotherapy-induced nausea and vomiting in combination with a 5-HT3 receptor antagonist and dexamethasone. A second NK-1 receptor antagonist netupitant was approved for use in October 2014. Phase III clinical trials of an additional NK-1 receptor antagonist rolapitant have been completed, and the data have been submitted for regulatory approval. A description of rolapitant and its role in chemotherapy-induced nausea and vomiting will be presented, along with a comparison of the other neurolinin-1 receptor antagonists aprepitant and netupitant.
authors.affiliation: a 1 World Health Organization, Eastern Europe.|b 2 Indiana University School of Medicine South Bend, South Bend, IN, USA.
authors.forename: Rudolph M
authors.initials: RM
authors.lastname: Navari
mesh_terms: D000818:Animals; D000932:Antiemetics / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D000077608:Aprepitant; D006801:Humans; D009025:Morpholines / Q000494:pharmacology / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D064729:Neurokinin-1 Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D011788:Quality of Life; D013141:Spiro Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*; D010879:Piperazines; D044482:Benzeneacetamides
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D000077608:Aprepitant; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D011725:Pyridines; D013141:Spiro Compounds; C508854:netupitant; D010879:Piperazines; D044482:Benzeneacetamides; C578834:rolapitant
keywords: 5-hydroxytryptamine-3 receptor antagonists; antiemetics; aprepitant; chemotherapy-induced nausea and vomiting; netupitant; rolapitant